<DOC>
	<DOCNO>NCT00002180</DOCNO>
	<brief_summary>The purpose study see safe effective give PMPA HIV-infected patient . This study also examine body handle PMPA .</brief_summary>
	<brief_title>A Study PMPA HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion Criteria Patients must : Laboratory diagnosis HIV infection . CD4 cell count &gt; = 200 cells/mm3 within 28 day prior entry . Plasma HIV RNA &gt; = 10,000 copies/ml within 28 day entry . Minimum life expectancy 12 month . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active , serious infection ( HIV ) require parental antibiotic therapy . Patients may consider recover least 2 week elapse follow cessation parental therapy enrollment . Active clinically significant medical problem include cardiac disease ( e.g. , symptoms ischemia , congestive heart failure , arrhythmia ) . Positive test Hepatitis B surface antigen Hepatitis C antibody serum . Patients follow prior condition exclude : History malignancy basal cell carcinoma cutaneous Kaposi 's sarcoma . Patients receive : Antiretroviral therapy , include nucleoside analog , nonnucleoside reverse transcriptase inhibitor , protease inhibitor investigational antiretroviral agent . Interferon interleukin therapy , aminoglycoside antibiotic , amphotericin B , cidofovir , diuretic , foscarnet , ganciclovir , itraconazole , fluconazole , ketoconazole ( topical allow ) , isoniazid , rifampin , rifabutin , clarithromycin , azithromycin , systemic chemotherapeutic agent , systemic corticosteroid , agent significant nephrotoxic potential , agent may inhibit compete elimination via active renal tubular secretion ( probenecid ) investigational agent . Within 2 week prior entry : Antiretroviral therapy , include nucleoside analog , nonnucleoside reverse transcriptase inhibitor , protease inhibitor investigational antiretroviral agent . Interferon interleukin therapy , aminoglycoside antibiotic , amphotericin B , cidofovir , diuretic , foscarnet , ganciclovir , itraconazole , fluconazole , ketoconazole ( topical allow ) , isoniazid , rifampin , rifabutin , clarithromycin , azithromycin , systemic chemotherapeutic agent , systemic corticosteroid , agent significant nephrotoxic potential , agent may inhibit compete elimination via active renal tubular secretion ( probenecid ) investigational agent . Active drug alcohol abuse demonstrate positive screen test drug abuse ( except marijuana drug use medical indication ) , substance abuse consider sufficient hinder patient compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 1999</verification_date>
	<keyword>Placebos</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Adenine</keyword>
</DOC>